Catheter Ablation and Device Therapy in Patients With Transthyretin Amyloid Cardiomyopathy: A Review of Non-Pharmacological Therapy.

J Arrhythm · 2026 · PMC12881705 · PMID 41659041

Europe PMC DOI

hedged sentence

0.2990

closest p · 6.0× alpha

0.2990

boldest claim

The sentences

showed a trendp = 0.299not close (p > 0.1)

demonstrated that tafamidis suppressed the worsening of echocardiographic parameters at an average of 16 ± 8 months after administration compared to pre‐treatment levels, and although not statistically significant, left atrial volume (LA volume index) showed a trend toward reduction (53.0 ± 17.7 vs. 49.0 ± 17.1, p = 0.299) [ 59 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.